Latest From OmniSeq Corp.
Immuno-oncology has significant diagnostic needs including identifying patients most likely to respond to therapies. Current diagnostic approaches often fall short, due in large part to the complexity of the biology driving therapy responsiveness. As such, the biopharma industry is exploring many emerging approaches covering tumor, immune and even microbiome-related pathways and biomarkers.
Brief profiles of these recently formed companies: Auspherix, Medella Health, OmniSeq, and Xtuit Pharmaceuticals.
Brief profiles of these recently formed companies: Auspherix, Medella Health, OmniSeq, and XTuit Pharmaceuticals.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.